Get the Flash Player to see this video.
MacroGenics’ mission is to discover, develop and deliver to patients novel biologics for the treatment of autoimmune disorders, cancer and infectious diseases. Learn more
Product Pipeline Highlights
View full chart| Program (Target) | Indication | Lead Opt. | Pre- Clin. |
Ph 1 |
Ph 2 |
Ph 3 |
|---|---|---|---|---|---|---|
| AUTOIMMUNE | ||||||
| Teplizumab* (CD3) | Diabetes | * | * | * | * | * |
| ONCOLOGY | ||||||
| MGAH22 (HER2) | Breast Cancer | * | * | * | * | * |
| INFECTIOUS DISEASES | ||||||
| MGAWN1 | West Nile Virus | * | * | * | * | * |
Type 1 Diabetes
.gif){kind=logo}
Recently diagnosed with Type 1 Diabetes? Take action. Learn more: teplizumab Learn more: Protégé Studies
Company Highlights
- Robust pipeline in autoimmunity, oncology and infectious diseases
- Global partnership with Eli Lilly for development of teplizumab
- Fully-integrated biologics capabilities across product development process
- Strong financial position and blue-chip investor base
- Experienced management team and highly collaborative corporate culture
Partnering
MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.
Learn more